We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Kite Pharma on Tuesday reported positive six-month results from a mid-stage study investigating its experimental CAR-T therapy axicabtagene ciloleucel in patients with chemorefractory aggressive B-cell non-Hodgkin lymphoma.